# SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Source: https://onco.cc/trials/nct04205630/  
OnCo record `nct04205630` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab duocarmazine in Endometrial cancer, run by Byondis B.V., completed.

## Summary

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma is a phase 2 interventional study registered as NCT04205630 by Byondis B.V., with 64 participants recorded, started 2020-05-28 and reaching its primary completion in 2023-01-26. Interventions recorded: SYD985. Conditions recorded: Endometrial Cancer.

Linked to the drug Trastuzumab duocarmazine because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04205630
- Phase: 2
- Setting: A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy
- Sponsor: Byondis B.V.
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT04205630: https://clinicaltrials.gov/study/NCT04205630

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Trastuzumab duocarmazine](https://onco.cc/drugs/trastuzumab-duocarmazine/)
- companies: [Byondis](https://onco.cc/companies/byondis/)

---
JSON: https://onco.cc/api/v1/entities/nct04205630.json